Comparison of health technology assessment for new medicines in France and England: an example based on ixazomib for patients with relapsed or refractory multiple myeloma

Introduction: The appraisal of medicines is often a complex and iterative process. We compared the health technology assessment (HTA) process in England and France taking as a case study the example of ixazomib for multiple myeloma. Methods: We undertook an analysis of eight relevant published docum...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Xavier Armoiry, Hans-Martin Spath, Aileen Clarke, Martin Connock, Paul Sutcliffe, Claude Dussart
פורמט: Artigo
שפה:Inglês
יצא לאור: Taylor & Francis Group 2019-01-01
סדרה:Journal of Market Access & Health Policy
נושאים:
nice
has
health technology assessment
france
england
ixazomib
multiple myeloma
גישה מקוונת:http://dx.doi.org/10.1080/20016689.2019.1648971
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים